Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Successful diabetes and weight loss drugs of Eli Lilly And Novo Nordisk – including Mounjaro, Zepbound, Ozempic And Wegova – Generated more than $ 40 billion in combined sales last year.
However, Novo Nordisk warned that the increase in versions of copying its weight loss drug in the United States and that Lilly competition in several markets should harm Wegovy Sales this year.
The two companies actively explore other medical uses of these GLP-1 drugs, aimed at expanding their market range and obtaining wider health insurance coverage.
The strategy has already had some success with WegovyFriday, obtaining the approval of the United States to treat a progressive liver condition.
Here are some of the other conditions that drugs are used and tested:
Alcohol dependence
A study conducted by the University of CopenhagenThe Psychiatric Center of Rigshospitalet, studies if the semaglutide – the main ingredient of Wegovy and Ozempic – can help reduce alcohol intake in 108 patients diagnosed with an alcohol consumption disorder and obesity.
Alzheimer’s disease
Novo Nordisk tests semaglutide in an advanced stage test in patients affected Alzheimer’s disease.
The study, which will recruit 1,840 patients, could have an initial data reading later this year.
Cardiovascular disease
Eli Lilly Tested the shooting – the main ingredient in Mounjaro and Zepbound – for patients with heart failure and obesity. Lilly said that she was entering around 700 people in the study, but the company said in May that she had withdrawn her American request for heart failure approval.
Novo won the approval of the American Food and Drug Administration in 2024 to use Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in overweight or obese adults without diabetes.
THE European Medicines Agency supported the use of the NOVO semaglutide to help alleviate the symptoms of heart failure in persons with obesity in September 2024.
Chronic kidney disease
Novo’s Ozempic is approved in the United States to reduce the risk of kidney failure and the progress of the disease, as well as the risk of death due to heart problems in diabetes patients with chronic kidney disease.
Lilly’s shooting is being evaluated in a mid-term study of patients with chronic kidney disease and obesity. Lilly plans to register up to 140 participants, the study should be completed next year.
Liver disease
Wegovy de Novo has become the first GLP-1 therapy approved in the United States to treat adults with steatohepatitis, or puree associated with metabolic dysfunction, based on the results of the first part of its test at an advanced stage.
The results of the second part, with around 1,200 patients, are expected in 2029.
Lilly’s shooting in February helped up to 74% of patients to obtain the absence of puree without empire of liver scars at 52 weeks, compared to 13% of patients on site, in a mid-term trial.
Neurological disorders
Researchers from Danish Headish Center test semaglutide as well as a very low calorie diet as treatment for recent idiopathic intracranial hypertension, a condition associated with obesity in which blood pressure Inside the head goes up.
The study scored around 50 patients and should be completed in October 2025.
Sleep apnea
Zepbound was approved by Food and Drug Administration of the United States for obstructive sleep apnea in December 2024, making it the first medication to directly treat patients with common disorder that causes respiratory disruption during sleep.
